Moleculin Biotech initiated with bullish view at H.C. Wainwright, here’s why

H.C. Wainwright analyst Vernon Bernardino initiated coverage of Moleculin Biotech with a Buy rating and $3 price target. The analyst says annamycin has potential to be a safe tool for cancer patients unable to access anthracyclines. The firm thinks Moleculin shares are underappreciated and represent an attractive value proposition.